265 results
8-K
EX-10.2
KA
Kineta Inc
4 Mar 22
Entry into a Material Definitive Agreement
4:15pm
, liabilities, suits, damages, fees, costs, and causes of action, and any and all other claims of every kind, nature and description whatsoever, both in law … (collectively, “Claims”). Notwithstanding the foregoing, Licensee shall not be released from any claims which, by their nature, survive the termination
8-K
EX-99.1
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
product candidates; investor returns; anticipated drug effects in human subjects; and other statements that are not historical in nature. The use … of 2023) and its ability to successfully initiate and complete clinical trials; (v) the nature, strategy and focus of the combined company; (vi
8-K
EX-10.3
037 eor7pk2qm0exx
30 Dec 20
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
4:44pm
425
z0jhlfeua69d am9je
11 Oct 22
Business combination disclosure
8:02am
425
syh529o9
29 Nov 22
Business combination disclosure
4:03pm
425
gqv jyy49
13 Oct 22
Business combination disclosure
4:03pm
425
izbl 60a8z
1 Dec 22
Business combination disclosure
4:04pm
425
k0vjp37jgy bd
28 Jun 22
Business combination disclosure
4:03pm
425
xauqlq2pzgysla6isgjg
17 Jun 22
Business combination disclosure
4:03pm
425
2rm4 vjtjh10z9aaa
12 Sep 22
Business combination disclosure
4:01pm
425
z0yfk6d
17 Oct 22
Business combination disclosure
4:03pm
425
88ir5lzh693vy
14 Sep 22
Business combination disclosure
4:04pm
425
jqsinhjxv6 d2
15 Nov 22
Business combination disclosure
4:03pm